OrienGene Biotechnology Ltd. Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (2005)

Organization Overview

First Clinical Trial
2012
NCT01935453
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

OrienGene Biotechnology Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

dacarbazine (dtic-dome) (1 trial)

orienx010 (1 trial)

Drugs in Phase 1 Trials (1)

hgm-csf herpes simplex virus injection (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Herpes Simplex (Phase 1)

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3